Advisory Research’s Altimmune ALT Stock Holding History

Advisory Research’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-44,216	Closed	-$727K	–	356
2022 Q4	$727K	Buy	44,216 +9,066	+26%	+$102K	0.07%	198
2022 Q3	$448K	Buy	+35,150	New	+$519K	0.04%	250

Other funds holding ALT

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Advisory Research's ALT Position: Q1 2023 in Review

Advisory Research sold out of Altimmune (ALT) in Q1 2023, closing a stake of 44,216 shares — an estimated $727K sold.

Advisory Research first reported a position in ALT in Q3 2022 and held it in 2 quarters. The position peaked at $727K in Q4 2022. 132 funds tracked by Wall St. Rank hold ALT as of Q1 2023.

Advisory Research reported no remaining Altimmune position as of Q1 2023 after selling out during the quarter.
Advisory Research sold 44,216 Altimmune shares in Q1 2023, an estimated $727K.
Advisory Research first reported a position in Altimmune in Q3 2022 and held it in 2 quarters.
Advisory Research's Altimmune position peaked at $727K in Q4 2022.
132 funds tracked by Wall St. Rank held Altimmune as of Q1 2023.

Based on Advisory Research's 13F filing for Q1 2023, filed 12 May 2023.